ARTICLE | Company News
MedImmune Inc., VasGene deal
September 12, 2005 7:00 AM UTC
MEDI and VasGene partnered to develop VasGene's preclinical MAbs targeting Eph receptor B4 (EphB4) and its ligand, Ephrin B2 (Efnb2), to treat cancer. MEDI is responsible for clinical development an...